Invention Grant
- Patent Title: Humanised ADAMTS13 binding antibodies
-
Application No.: US16638677Application Date: 2018-06-13
-
Publication No.: US11339226B2Publication Date: 2022-05-24
- Inventor: Karen Vanhoorelbeke , Shannen F. Deconinck , An-Sofie Schelpe
- Applicant: Katholieke Universiteit Leuven
- Applicant Address: BE Leuven
- Assignee: Katholieke Universiteit Leuven
- Current Assignee: Katholieke Universiteit Leuven
- Current Assignee Address: BE Leuven
- Agency: Dinsmore & Shohl, LLP
- Priority: GB1709379 20170613
- International Application: PCT/EP2018/065617 WO 20180613
- International Announcement: WO2018/229103 WO 20181220
- Main IPC: C07K16/40
- IPC: C07K16/40 ; A61P7/04 ; A61K39/00
Abstract:
The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
Public/Granted literature
- US20200308303A1 HUMANISED ADAMTS13 BINDING ANTIBODIES Public/Granted day:2020-10-01
Information query
